Therapeutic strategies to alter the oxygen affinity of sickle hemoglobin

Hematology/Oncology Clinics of North America

Volumn 28, Issue 2, 2014, Pages 217-231

  Safo, Martin K ^a   Kato, Gregory J ^b  

^a VIRGINIA COMMONWEALTH UNIVERSITY   (United States)

^b UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

Author keywords

5 HMF; Antisickling; Hemoglobin allosteric effectors; R state; Sickle cell

Indexed keywords

5 HYDOXYMETHYL 2 FURFURAL; AES 103; ANTISICKLING AGENT; HEMOGLOBIN S; UNCLASSIFIED DRUG; 5-METHYL-2-FURFURAL; FURFURAL; OXYGEN; PROTEIN BINDING;

ALLOSTERISM; CLINICAL TRIAL (TOPIC); DRUG DESIGN; HUMAN; OXYGEN AFFINITY; PRIORITY JOURNAL; PROTEIN QUATERNARY STRUCTURE; REVIEW; SICKLE CELL; SICKLE CELL ANEMIA; ANALOGS AND DERIVATIVES; ANEMIA, SICKLE CELL; ANIMAL; BINDING COMPETITION; DRUG EFFECTS; METABOLISM; MOUSE;

ANEMIA, SICKLE CELL; ANIMALS; ANTISICKLING AGENTS; BINDING, COMPETITIVE; FURALDEHYDE; HEMOGLOBIN, SICKLE; HUMANS; MICE; OXYGEN; PROTEIN BINDING;

EID: 84896734559     PISSN: 08898588     EISSN: 15581977     Source Type: Journal    
DOI: 10.1016/j.hoc.2013.11.001     Document Type: Review

References (100)

1. Riggs S.A., Wells M. The oxygen equilibrium of sickle-cell hemoglobin. Biochim Biophys Acta 1961, 50:243-248.
2. Charache S., Grisolia S., Fiedler A.J., et al. Effect of 2,3-diphosphoglycerate on oxygen affinity of blood in sickle cell anemia. JClin Invest 1970, 49:806-812.
3. Seakins M., Gibbs W.N., Milner P.F., et al. Erythrocyte Hb-S concentration. An important factor in the low oxygen affinity of blood in sickle cell anemia. JClin Invest 1973, 52:422-432.
4. Milner P.F. Oxygen transport in sickle cell anemia. Arch Intern Med 1974, 133:565-572.
5. 2 regulation of erythrocyte properties. Blood 2008, 111:932-938.
6. Weber R.E., Voelter W., Fago A., et al. Modulation of red cell glycolysis: interactions between vertebrate hemoglobins and cytoplasmic domains of band 3 red cell membrane proteins. Am J Physiol Regul Integr Comp Physiol 2004, 287:R454-R464.
7. 2 content, glycolysis, and antioxidant capacity. Blood 2013, 121:1651-1662.
8. Poillon W.N., Kim B.C., Welty E.V., et al. The effect of 2,3-diphosphoglycerate on the solubility of deoxyhemoglobin S. Arch Biochem Biophys 1986, 249:301-305.
9. Poillon W.N., Kim B.C. 2,3-Diphosphoglycerate and intracellular pH as interdependent determinants of the physiologic solubility of deoxyhemoglobin S. Blood 1990, 76:1028-1036.
10. Poillon W.N., Robinson M.D., Kim B.C. Deoxygenated sickle hemoglobin. Modulation of its solubility by 2,3-diphosphoglycerate and other allosteric polyanions. JBiol Chem 1985, 260:13897-13900.
11. Jensen F.B. The dual roles of red blood cells in tissue oxygen delivery: oxygen carriers and regulators of local blood flow. JExp Biol 2009, 212:3387-3393.
12. Beutler E., Paniker N.V., West C. The effect of 2,3-DPG on the sickling phenomenon. Blood 1971, 37:184-186.
13. Swerdlow P.H., Bryan R.A., Bertles J.F., et al. Effect of 2, 3-diphosphoglycerate on the solubility of deoxy-sickle hemoglobin. Hemoglobin 1977, 1:527-537.
14. Poillon W.N., Kim B.C., Labotka R.J., et al. Antisickling effects of 2,3-diphosphoglycerate depletion. Blood 1995, 85:3289-3296.
15. Adhikary P.K., Hara S., Dwivedi C., et al. Vaso-occlusive crisis episodes in sickle cell disease. JMed 1986, 17:227-240.
16. Perutz M.F., Wilkinson A.J., Paoli M., et al. The stereochemical mechanism of the cooperative effects in hemoglobin revisited. Annu Rev Biophys Biomol Struct 1998, 27:1-34.
17. Perutz M.F., Fermi G., Luisi B., et al. Stereochemistry of cooperative mechanisms in hemoglobin. Cold Spring Harb Symp Quant Biol 1987, 52:555-565.
18. Perutz M.F. Nature of haem-haem interaction. Nature 1972, 237:495-499.
19. Perutz M.F. Stereochemical mechanism of cooperative effects in haemoglobin. Biochimie 1972, 54:587-588.
20. Monod J., Wyman J., Changeux J.P. On the nature of allosteric transitions: a plausible model. JMol Biol 1965, 12:88-118.
21. Koshland D.E., Nemethy G., Filmer D. Comparison of experimental binding data and theoretical models in proteins containing subunits. Biochemistry 1966, 5:365-385.
22. Sawicki C.A., Gibson Q.H. Quaternary conformational changes in human hemoglobin studied by laser photolysis of carboxyhemoglobin. JBiol Chem 1976, 251:1533-1542.
23. Samuni U., Dantsker D., Juszczak L.J., et al. Spectroscopic and functional characterization of T state hemoglobin conformations encapsulated in silica gels. Biochemistry 2004, 43:13674-13682.
24. Song X.J., Simplaceanu V., Ho N.T., et al. Effector-induced structural fluctuation regulates the ligand affinity of an allosteric protein: binding of inositol hexaphosphate has distinct dynamic consequences for the T and R states of hemoglobin. Biochemistry 2008, 47:4907-4915.
25. Wilson J., Phillips K., Luisi B. The crystal structure of horse deoxyhaemoglobin trapped in the high-affinity (R) state. JMol Biol 1996, 264:743-756.
26. Schumacher M.A., Dixon M.M., Kluger R., et al. Allosteric transition intermediates modelled by crosslinked haemoglobins. Nature 1995, 375:84-87.
27. Abraham D.J., Peace R.A., Randal R.S., et al. X-ray diffraction study of did and tetra-ligated T-state hemoglobin from high salt crystals. JMol Biol 1992, 227:480-492.
28. Cavanaugh J.S., Rogers P.H., Anyone A. Crystallographic evidence for a new ensemble of ligand-induced allosteric transitions in hemoglobin: the T-to-T(high) quaternary transitions. Biochemistry 2005, 44:6101-6121.
29. Jenkins J.D., Moseyed F.N., Danso-Danquah R., et al. Structure of relaxed-state human hemoglobin: insight into ligand uptake, transport and release. Acta Crystallogr D Biol Crystallogr 2009, 65:41-48.
30. Janin J., Wodak S.J. The quaternary structure of carbonmonoxy hemoglobin ypsilanti. Proteins 1993, 15:1-4.
31. Yonetani T., Tsuneshige A. The global allostery model of hemoglobin: an allosteric mechanism involving homotropic and heterotropic interactions. CR Biol 2003, 326:523-532.
32. Henry E.R., Bettati S., Hofrichter J., et al. Atertiary two-state allosteric model for hemoglobin. Biophys Chem 2002, 98:149-164.
33. Safo M.K., Abraham D.J. The enigma of the liganded hemoglobin end state: a novel quaternary structure of human carbonmonoxy hemoglobin. Biochemistry 2005, 44:8347-8359.
34. Safo M.K., Burnett J.C., Moseyed F.N., et al. Structure of human carbonmonoxyhemoglobin at 2.16 A: a snapshot of the allosteric transition. Acta Crystallogr D Biol Crystallogr 2002, 58:2031-2037.
35. Mueser T.C., Rogers P.H., Anyone A. Interface sliding as illustrated by the multiple quaternary structures of liganded hemoglobin. Biochemistry 2000, 39:15353-15364.
36. Silva M.M., Rogers P.H., Anyone A. Athird quaternary structure of human hemoglobin A at 1.7-A resolution. JBiol Chem 1992, 267:17248-17256.
37. Safo M.K., Ahmed M.H., Ghatge M.S., et al. Hemoglobin-ligand binding: understanding Hb function and allostery on atomic level. Biochim Biophys Acta 2011, 1814:797-809.
38. Gong Q., Simplaceanu V., Lukin J.A., et al. Quaternary structure of carbonmonoxyhemoglobins in solution: structural changes induced by the allosteric effector inositol hexaphosphate. Biochemistry 2006, 45:5140-5148.
39. Lukin J.A., Kontaxis G., Simplaceanu V., et al. Quaternary structure of hemoglobin in solution. Proc Natl Acad Sci USA 2003, 100:517-520.
40. Schumacher M.A., Zheleznova E.E., Poundstone K.S., et al. Allosteric intermediates indicate R2 is the liganded hemoglobin end state. Proc Natl Acad Sci USA 1997, 94:7841-7844.
41. Abdulmalik O., Ghatge M.S., Moseyed F.N., et al. Crystallographic analysis of human hemoglobin elucidates the structural basis of the potent and dual antisickling activity of pyridyl derivatives of vanillin. Acta Crystallogr D Biol Crystallogr 2011, 67:920-928.
42. Safo M.K., Abdulmalik O., Danso-Danquah R., et al. Structural basis for the potent antisickling effect of a novel class of five-membered heterocyclic aldehydic compounds. JMed Chem 2004, 47:4665-4676.
43. Anyone A. X-ray diffraction study of binding of 2,3-diphosphoglycerate to human deoxyhaemoglobin. Nature 1972, 237:146-149.
44. Richard V., Dodson G.G., Mauguen Y. Human deoxyhaemoglobin-2,3-diphosphoglycerate complex low-salt structure at 2.5 A resolution. JMol Biol 1993, 233:270-274.
45. Safo M.K., Bruno S. Allosteric effectors of hemoglobin: past, present and future. Chemistry and biochemistry of oxygen therapeutics: from transfusion to artificial blood 2011, 285-300. John Wiley, Hoboken, NJ. A. Mozzarelli, S. Bettati (Eds.).
46. Nnamani I.N., Joshi G.S., Danso-Danquah R., et al. Pyridyl derivatives of benzaldehyde as potential antisickling agents. Chem Biodivers 2008, 5:1762-1769.
47. Safo M.K., Moure C.M., Burnett J.C., et al. High-resolution crystal structure of deoxy hemoglobin complexed with a potent allosteric effector. Protein Sci 2001, 10:951-957.
48. Abraham D.J., Safo M.K., Boyiri T., et al. How allosteric effectors can bind to the same protein residue and produce opposite shifts in the allosteric equilibrium. Biochemistry 1995, 34:15006-15020.
49. Boyiri T., Safo M.K., Danso-Danquah R.E., et al. Bisaldehyde allosteric effectors as molecular ratchets and probes. Biochemistry 1995, 34:15021-15036.
50. Abraham D.J., Wireko F.C., Randal R.S., et al. Allosteric modifiers of hemoglobin: 2-[4-[[(3,5-disubstituted anilino)carbonyl]methyl]phenoxy]-2-methylpropionic acid derivatives that lower the oxygen affinity of hemoglobin in red cell suspensions, in whole blood, and invivo in rats. Biochemistry 1992, 31:9141-9149.
51. Randal R.S., Mahran M.A., Mehanna A.S., et al. Allosteric modifiers of hemoglobin. 1. Design, synthesis, testing, and structure-allosteric activity relationship of novel hemoglobin oxygen affinity decreasing agents. JMed Chem 1991, 34:752-757.
52. Chen Q., Lalezari I., Nagel R.L., et al. Liganded hemoglobin structural perturbations by the allosteric effector L35. Biophys J 2005, 88:2057-2067.
53. Lalezari I., Lalezari P., Poyart C., et al. New effectors of human hemoglobin: structure and function. Biochemistry 1990, 29:1515-1523.
54. Hou H., Khan N., Grinberg O.Y., et al. The effects of Efaproxyn (efaproxiral) on subcutaneous RIF-1 tumor oxygenation and enhancement of radiotherapy-mediated inhibition of tumor growth in mice. Radiat Res 2007, 168:218-225.
55. Grinberg O.Y., Miyake M., Hou H., et al. The dose-dependent effect of RSR13, a synthetic allosteric modifier of hemoglobin, on physiological parameters and brain tissue oxygenation in rats. Adv Exp Med Biol 2003, 530:287-296.
56. Khandelwal S.R., Randal R.S., Lin P.S., et al. Enhanced oxygenation invivo by allosteric inhibitors of hemoglobin saturation. Am J Physiol 1993, 265:H1450-H1453.
57. Kunert M.P., Liard J.F., Abraham D.J. RSR-13, an allosteric effector of hemoglobin, increases systemic and iliac vascular resistance in rats. Am J Physiol 1996, 271:H602-H613.
58. Suh J.H., Stea B., Nabid A., et al. Phase III study of efaproxiral as an adjunct to whole-brain radiation therapy for brain metastases. JClin Oncol 2006, 24:106-114.
59. Scott C., Suh J., Stea B., et al. Improved survival, quality of life, and quality-adjusted survival in breast cancer patients treated with efaproxiral (efaproxyn) plus whole-brain radiation therapy for brain metastases. Am J Clin Oncol 2007, 30:580-587.
60. Wireko F.C., Abraham D.J. X-ray diffraction study of the binding of the antisicklingagent 12C79 to human hemoglobin. Proc Natl Acad Sci USA 1991, 88:2209-2211.
61. Abraham D.J., Mehanna A.S., Wireko F.C., et al. Vanillin, a potential agent for the treatment of sickle cell anemia. Blood 1991, 77:1334-1341.
62. Swerdlow P.S., Orringer E.P., Abraham D.J. Dietary management of sickle cell anaemia with vanillin. Free Radic Res Commun 1992, 17:351-352.
63. Abdulmalik O., Safo M.K., Chen Q., et al. 5-Hydroxymethyl-2-furfural modifies intracellular sickle haemoglobin and inhibits sickling of red blood cells. Br J Haematol 2005, 128:552-561.
64. Zaugg R.H., Walder J.A., Klotz I.M. Schiff base adducts of hemoglobin. Modifications that inhibit erythrocyte sickling. JBiol Chem 1977, 252:8542-8548.
65. Mehanna A.S. Sickle cell anemia and antisickling agents then and now. Curr Med Chem 2001, 8:79-88.
66. Sheh L., Mokotoff M., Abraham D.J. Design, synthesis, and testing of potential antisickling agents. 9. Cyclic tetrapeptide homologs as mimics of the mutation site of hemoglobin S. Int J Pept Protein Res 1987, 29:509-520.
67. Patwa D.C., Abraham D.J., Hung T.C. Design, synthesis, and testing of potential antisickling agents. 6. Rheologic studies with active phenoxy and benzyloxy acids. Blood Cells 1987, 12:589-601.
68. Abraham D.J., Perutz M.F., Phillips S.E. Physiological and x-ray studies of potential antisickling agents. Proc Natl Acad Sci USA 1983, 80:324-328.
69. Perutz M.F., Fermi G., Abraham D.J., et al. Hemoglobin as a receptor of drugs and peptides: X-ray studies of the stereochemistry of binding. JAm Chem Soc 1986, 108:1064-1078.
70. Abraham D.J., Gazze D.M., Kennedy P.E., et al. Design, synthesis, and testing of potential antisickling agents. 5. Disubstituted benzoic acids designed for the donor site and proline salicylates designed for the acceptor site. JMed Chem 1984, 27:1549-1559.
71. Abraham D.J., Mokotoff M., Sheh L., et al. Design, synthesis, and testing of antisickling agents. 2. Proline derivatives designed for the donor site. JMed Chem 1983, 26:549-554.
72. Sunshine H.R., Hofrichter J., Eaton W.A. Requirement for therapeutic inhibition of sickle haemoglobin gelation. Nature 1978, 275:238-240.
73. Wood W.G., Pembrey M.E., Serjeant G.R., et al. Hb F synthesis in sickle cell anaemia: a comparison of Saudi Arab cases with those of African origin. Br J Haematol 1980, 45:431-445.
74. Pembrey M.E., Wood W.G., Weatherall D.J., et al. Fetal haemoglobin production and the sickle gene in the oases of eastern Saudi Arabia. Br J Haematol 1978, 40:415-429.
75. Garel M.C., Domenget C., Caburi-Martin J., et al. Covalent binding of glutathione to hemoglobin. I. Inhibition of hemoglobin S polymerization. JBiol Chem 1986, 261:14704-14709.
76. Caburi-Martin J., Garel M.C., Domenget C., et al. Contact inhibition within hemoglobin S polymer by thiol reagents. Biochim Biophys Acta 1986, 874:82-89.
77. Garel M.C., Domenget C., Galacteros F., et al. Inhibition of erythrocyte sickling by thiol reagents. Mol Pharmacol 1984, 26:559-565.
78. Park S., Hayes B.L., Marankan F., et al. Regioselective covalent modification of hemoglobin in search of antisickling agents. JMed Chem 2003, 46:936-953.
79. Zaugg R.H., Walder J.A., Walder R.Y., et al. Modification of hemoglobin with analogs of aspirin. JBiol Chem 1980, 255:2816-2821.
80. Walder J.A., Zaugg R.H., Iwaoka R.S., et al. Alternative aspirins as antisickling agents: Acetyl-3,5-dibromosalicylic acid. Proc Natl Acad Sci USA 1977, 74:5499-5503.
81. Walder J.A., Zaugg R.H., Walder R.Y., et al. Diaspirins that cross-link beta chains ofhemoglobin: Bis(3,5-dibromosalicyl) succinate and bis(3,5-dibromosalicyl) fumarate. Biochemistry 1979, 18:4265-4270.
82. Beddell C.R., Goodford P.J., Kneen G., et al. Substituted benzaldehydes designed to increase the oxygen affinity of human haemoglobin and inhibit the sickling of sickle erythrocytes. Br J Pharmacol 1984, 82:397-407.
83. Merrett M., Stammers D.K., White R.D., et al. Characterization of the binding of theanti-sickling compound, BW12C, to haemoglobin. Biochem J 1986, 239:387-392.
84. Keidan A.J., Franklin I.M., White R.D., et al. Effect of BW12C on oxygen affinity of haemoglobin in sickle-cell disease. Lancet 1986, 1:831-834.
85. Fitzharris P., McLean A.E., Sparks R.G., et al. The effects in volunteers of BW12C, a compound designed to left-shift the blood-oxygen saturation curve. Br J Clin Pharmacol 1985, 19:471-481.
86. Arya R., Rolan P.E., Wootton R., et al. Tucaresol increases oxygen affinity and reduces haemolysis in subjects with sickle cell anaemia. Br J Haematol 1996, 93:817-821.
87. Rolan P.E., Mercer A.J., Wootton R., et al. Pharmacokinetics and pharmacodynamics of tucaresol, an antisickling agent, in healthy volunteers. Br J Clin Pharmacol 1995, 39:375-380.
88. Rolan P.E., Parker J.E., Gray S.J., et al. The pharmacokinetics, tolerability and pharmacodynamics of tucaresol (589C80; 4[2-formyl-3-hydroxyphenoxymethyl] benzoic acid), a potential anti-sickling agent, following oral administration to healthy subjects. Br J Clin Pharmacol 1993, 35:419-425.
89. Rhodes J. Discovery of immunopotentiatory drugs: current and future strategies. Clin Exp Immunol 2002, 130:363-369.
90. Safo M.K., Boyiri T., Burnett J.C., et al. X-ray crystallographic analyses of symmetrical allosteric effectors of hemoglobin: compounds designed to link primary and secondary binding sites. Acta Crystallogr D Biol Crystallogr 2002, 58:634-644.
91. Zhang C., Li X., Lian L., et al. Anti-sickling effect of MX-1520, a prodrug of vanillin: an invivo study using rodents. Br J Haematol 2004, 125:788-795.
92. Available at: Accessed January 1, 2014. http://ntp.niehs.nih.gov/go/TS-M950006.
93. Rhoda M.D., Martin J., Blouquit Y., et al. Sickle cell hemoglobin fiber formation strongly inhibited by the Stanleyville II mutation (alpha 78 Asn leads to Lys). Biochem Biophys Res Commun 1983, 111:8-13.
94. Mendelsohn L.G., Pedoeim L., van Beers E.J., et al. Effect of Aes-103 anti-sickling agent on oxygen affinity and stability of red blood cells from patients with sickle cell anemia. ASH Annual Meeting Abstracts. Blood 2012, 120(21):85.
95. van Beers E.J., Samsel L., Mendelsohn L.G., et al. Imaging flow cytometry for fully automated quantification of percentage of sickled cells in sickle cell anemia. ASH Annual Meeting Abstracts. Blood 2012, 120(21):2105.
96. Gatterer H., Greilberger J., Philippe M., et al. Short-term supplementation with alpha-ketoglutaric acid and 5-hydroxymethylfurfural does not prevent the hypoxia induced decrease of exercise performance despite attenuation of oxidative stress. Int J Sports Med 2013, 34:1-7.
97. Matzi V., Lindenmann J., Muench A., et al. The impact of preoperative micronutrient supplementation in lung surgery. A prospective randomized trial of oral supplementation of combined alpha-ketoglutaric acid and 5-hydroxymethylfurfural. Eur J Cardiothorac Surg 2007, 32:776-782.
98. Stern W., Mathews D., McKew J., et al. A phase 1, first-in-man, dose-response study of Aes-103 (5-HMF), an anti-sickling, allosteric modifier of hemoglobin oxygen affinity in healthy Norman volunteers. ASH Annual Meeting Abstracts. Blood 2012, 120(21):3210.
99. Padmos M.A., Roberts G.T., Sackey K., et al. Two different forms of homozygous sickle cell disease occur in Saudi Arabia. Br J Haematol 1991, 79:93-98.
100. el-Hazmi M.A. Heterogeneity and variation of clinical and haematological expression of haemoglobin S in Saudi Arabs. Acta Haematol 1992, 88:67-71.